Sudeep Pharma IPO Date, Review, Price, Allotment Details
The Sudeep Pharma IPO will open on November 21, 2025, and close on November 25, 2025. It is a book-built issue, through which the company aims to raise approximately ₹895 crore. This includes a fresh issue worth ₹95 crore and an offer for sale of up to 1,34,90,726 equity shares, each having a face value of ₹1.
The IPO price band has been set between ₹563 and ₹593 per share. The allocation structure includes 50% for QIBs, 15% for HNIs, and 35% for retail investors. The shares are scheduled to be listed on both the BSE and NSE on November 28, 2025, while the IPO allotment date is November 26, 2025.
Financially, the company posted revenues of ₹511.33 crore in 2025, up from ₹465.38 crore in 2024. Its profit also rose to ₹138.69 crore in 2025, compared to ₹133.15 crore in the previous year. Based on these financial trends, the IPO appears to be a promising option for long-term investors.
Sudeep Pharma IPO Details
Sudeep Pharma IPO Market Lot
The minimum market lot for the Sudeep Pharma IPO is 25 shares, requiring an application amount of ₹14,825. Retail investors can apply for up to 13 lots, which totals 325 shares and an investment amount of ₹1,92,725.
IPO Reservation
Sudeep Pharma IPO Anchor Investors
Sudeep Pharma IPO Dates
The Sudeep Pharma IPO will open on November 21 and close on November 25. The allotment results will be finalized on November 26, and the IPO is scheduled to list on November 28.
Promoters and Holding Pattern
The company’s promoters include Sujit Jaysukh Bhayani, Avani Sujit Bhayani, Shanil Sujit Bhayani, Sujeet Jaysukh Bhayani (HUF), Riva Resources Private Limited, and the Bhayani Family Trust.
Objects of the Issue & Utilisation of Proceeds
About Sudeep Pharma IPO
Sudeep Pharma Limited, established in 1989, is a leading manufacturer of excipients and specialty ingredients used across the pharmaceutical, food, and nutrition sectors. The company contributes to the global healthcare ecosystem by supplying over 200 products to more than 100 countries. To drive innovation, Sudeep Pharma leverages its own in-house technologies, including encapsulation, spray drying, granulation, trituration, liposomal preparation, and advanced mixing processes.
The company operates through two main business verticals:
Pharmaceutical, Food, and Nutrition – offering essential mineral salts such as calcium, zinc, iron, potassium, magnesium, sodium, and copper.
Specialty Ingredients – covering micronutrient premixes, encapsulated ingredients, granulated minerals, and triturated blends.
Additionally, Sudeep Pharma manages six manufacturing facilities with a combined production capacity of 50,000 MT, further strengthening its operational scale and global presence.
Sudeep Pharma IPO Company Financial Report
Amount ₹ in Crores
Sudeep Pharma IPO Valuation – FY2025
Check Sudeep Pharma IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.
Peer Group Comparison
- There are no peer group companies listed in India.
IPO Lead Managers aka Merchant Bankers
- ICICI Securities Ltd.
- IIFL Capital Services Ltd.
Company Address
Sudeep Pharma Ltd.
129/1/A,
GIDC Estate,
Nandesari,
Vadodara, Gujarat, 391340
Phone: +91 265 284 0656
Email: cs.sudeep@sudeepgroup.com
Website: https://www.sudeeppharma.com/
IPO Registrar
MUFG Intime India Pvt. Ltd.
Phone: +91-22-4918 6270
Email: sudeeppharma.ipo@in.mpms.mufg.com
Website: https://in.mpms.mufg.com/Initial_Offer/public-issues.html